TNFRSF13B and Miyoshi myopathy: As for patient survival, we found that TNFRSF13B upregulation, instead of TNFRSF17, was associated with a lower 3-year survival rate in MM patients, ascribed to TNFRSF13B overexpression (Figure 2F).